SEC Form 4 · accession 0001177648-18-000033
ENANTA PHARMACEUTICALS INC · ENTA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nathalie Adda
Officer — Sr. VP & Chief Medical Officer
Period of report
Aug 20, 2018
Accepted (ET)
Aug 21, 2018 · 6:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001177648
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 20, 2018 | M | 2,955 | $43.46 | A | 4,465 | D | |
| Common StockF2 | Aug 20, 2018 | S | 572 | $90.5798 | D | 3,893 | D | |
| Common StockF3 | Aug 20, 2018 | S | 700 | $91.4886 | D | 3,193 | D | |
| Common StockF4 | Aug 20, 2018 | S | 2,224 | $92.6843 | D | 969 | D | |
| Common StockF5 | Aug 20, 2018 | S | 659 | $93.4941 | D | 310 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F6 | $43.46 | Aug 20, 2018 | M | 2,955 | D | — | Jun 29, 2025 | Common Stock | 2,955 | 75,225 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018.
- F2The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $90.30 to $90.74, inclusive.
- F3The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $91.35 to $91.67, inclusive.
- F4The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $92.00 to $92.95, inclusive.
- F5The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $93.07 to $94.03, inclusive.
- F6The option, representing a right to purchase a total of 90,000 shares, became or will become exercisable as follows: twenty-five percent (25%) of the shares subject to such option became exercisable on June 29, 2016 (the "Anniversary Date") and the remainder became or will become exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over three years after the Anniversary Date.